The present invention provides a compound represented by the general formula (I) of the present invention, which has EP 1 receptor antagonism: [wherein A represents a benzene ring, a pyridine ring, or the like； Y 1 represents a C 1-6 alkylene group or the like； Y 2 represents a single bond or the like； Z represents -C(=O)-NHSO 2 R 6 , an acidic 5-membered hetero ring group, or the like； R 1 represents a hydrogen atom or the like； R 2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like； R 3 represents a halogen atom, a C 1-6 alkoxy group, or the like； R 4 represents a hydrogen atom, a halogen atom, or the like； R 5 represents a hydrogen atom or the like； and R 6 represents a C 1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
